We are live on ! Find out more
BGM

Burkehill Global Management Portfolio holdings

AUM $2.02B
1-Year Est. Return 85.32%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+85.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$498M
Cap. Flow
+$466M
Cap. Flow %
23.08%
Top 10 Hldgs %
41.93%
Holding
218
New
58
Increased
7
Reduced
12
Closed
36

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$147M
2
DLR icon
Digital Realty Trust
DLR
+$128M
3
FANG icon
Diamondback Energy
FANG
+$114M
4
NRG icon
NRG Energy
NRG
+$70.8M
5
SNDK
Sandisk
SNDK
+$70.6M

Top Sells

Rank Stock Value
1
ITT icon
ITT
ITT
+$60.7M
2
SOFI icon
SoFi Technologies
SOFI
+$52.4M
3
NDAQ icon
Nasdaq
NDAQ
+$48.6M
4
EL icon
Estee Lauder
EL
+$47.1M
5
ROL icon
Rollins
ROL
+$43.5M

Sector Composition

Rank Sector Weight
1 Healthcare 22.71%
2 Technology 19.4%
3 Industrials 18.69%
4 Energy 10.65%
5 Real Estate 8.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
151
Wave Life Sciences
WVE
$1.12B
$1.09M 0.05%
150,000
– –
RCUS icon
152
Arcus Biosciences
RCUS
$3.57B
$1.08M 0.05%
50,000
– –
CTMX icon
153
CytomX Therapeutics
CTMX
$705M
$1.06M 0.05%
+225,000
New +$1.14M
KMTS
154
Kestra Medical Technologies
KMTS
$1.23B
$997K 0.05%
50,000
– –
AXGN icon
155
Axogen
AXGN
$2.1B
$994K 0.05%
+30,000
New +$975K
INR
156
Infinity Natural Resources
INR
$248M
$881K 0.04%
50,000
– –
MNTN
157
MNTN Inc
MNTN
$634M
$880K 0.04%
100,000
– –
PHAT icon
158
Phathom Pharmaceuticals
PHAT
$912M
$833K 0.04%
+75,000
New +$947K
ZBIO
159
Zenas BioPharma
ZBIO
$1.92B
$782K 0.04%
+40,000
New +$898K
AGBK
160
AGI Inc
AGBK
$1.07B
$727K 0.04%
+100,000
New +$1.01M
LXEO icon
161
Lexeo Therapeutics
LXEO
$366M
$718K 0.04%
125,000
– –
RLMD icon
162
Relmada Therapeutics
RLMD
$544M
$665K 0.03%
+105,263
New +$498K
ATAI icon
163
AtaiBeckley Inc
ATAI
$2.66B
$655K 0.03%
185,000
– –
OMDA
164
Omada Health Inc
OMDA
$1.22B
$629K 0.03%
50,000
– –
CARL
165
Carlsmed
CARL
$294M
$453K 0.02%
50,000
– –
ZURA icon
166
Zura Bio
ZURA
$497M
$446K 0.02%
+75,000
New +$453K
LMRI
167
Lumexa Imaging Holdings
LMRI
$1.05B
$430K 0.02%
50,000
– –
ACET icon
168
Adicet Bio
ACET
$72.8M
$426K 0.02%
62,500
– –
BTGO
169
BitGo Holdings
BTGO
$559M
$412K 0.02%
+50,000
New +$547K
FULC icon
170
Fulcrum Therapeutics
FULC
$248M
$384K 0.02%
50,000
– –
AGMB
171
AgomAb Therapeutics NV
AGMB
$616M
$367K 0.02%
+35,000
New +$496K
CNTB
172
Connect Biopharma Holdings
CNTB
$135M
$360K 0.02%
+150,000
New +$391K
MANE
173
Veradermics Inc
MANE
$4.58B
$316K 0.02%
+5,000
New +$252K
CRVS icon
174
Corvus Pharmaceuticals
CRVS
$1.1B
$293K 0.01%
+20,000
New +$319K
GUTS icon
175
Fractyl Health
GUTS
$123M
$229K 0.01%
500,000
– –
5 6
7
8 9

Similar funds

AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
NIM
NXG Investment Management Dallas, Texas $2.02B AUM 30.38% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.03B AUM 32.21% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.03B AUM 26.86% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Burkehill Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Burkehill Global Management held 218 positions worth $2.02B, up 33% from $1.52B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Burkehill Global Management deployed $466M of net new capital in Q1 2026, opening 58 new positions and adding to 7 existing holdings. Its largest new stake was Eli Lilly: 145,000 shares worth $133M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 19% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Nebius Group N.V., an estimated $22.5M trimmed.

  • Burkehill Global Management's largest Q1 2026 buy was Eli Lilly: 145,000 shares worth $133M.
  • Burkehill Global Management added most to Medline Inc in Q1 2026, an estimated $43.4M increase.
  • Burkehill Global Management's biggest Q1 2026 reduction was Nebius Group N.V., cutting an estimated $22.5M.
  • Burkehill Global Management fully exited ITT in Q1 2026, selling an estimated $60.7M.
  • Burkehill Global Management's ten largest holdings make up 42% of its $2.02B portfolio in Q1 2026.
  • Burkehill Global Management opened 58 new positions and closed 36 in Q1 2026.
  • Burkehill Global Management's portfolio value rose 33% quarter-over-quarter to $2.02B.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.